MiMedx Group, Inc (MDXG) — 分析摘要
MiMedx Group, Inc（MDXG）的市值为625.57百万美元，最近一年的营收同比增长了+20.0%。净利润率为11.6%。当前市盈率为20.4倍。
核心要点
- 营收同比变化+20.0%
- 净利润率11.6%
- 市盈率20.4倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比，MDXG的营收增长为+20.0%，市盈率为20.4倍。
MiMedx Group, Inc (MDXG)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
808
总部
MARIETTA, GA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。